CONTEMPORARY MARKERS AND HISTOLOGICAL FEATURES OF PROSTATE CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Increasing prostate cancer incidence rates highlight the importance of more timely diagnosis with the ultimate aim of reducing cancer-specific mortality, while maintaining patients’ quality of life. Until recently, digital rectal examination and prostate-specific antigen have been used for diagnosis of prostate cancer. Recent advances in medical technologies and laboratory testing have led to introducing new cancer markers into clinical practice. The most highly demanded of them are the PCA-3, -2proPSA and Prostate Health Index. Despite the wide range of laboratory tests, a prostate biopsy with a subsequent morphological examination of biopsy tissue specimens remains the only way to definitively diagnose prostate cancer.

Full Text

Restricted Access

About the authors

A. O Vasilyev

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: alexvasilyev@me.com
PhD, Teaching Assistant at the Department of Urology

E. A Prilepskaya

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: prilepskayae@mail.ru
Department of Urology

M. V Kovylina

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: dr.kovylina@gmail.com
Department of Urology

A. V Govorov

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: dr.govorov@gmail.com
Department of Urology

A. V Sadchenko

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: dос.sadchenko@yandex.ru
Department of Urology

A. V Sidorenkov

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: avsid-v@mail.ru
Department of Urology

D. Yu Pushkar

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: pushkardm@mail.ru
Department of Urology

References

  1. Пушкарь Д.Ю. Робот-ассистированная простатэктомия: руководство для врачей. М.: ГЭОТАР-Медиа. 2014. 384 c
  2. Пушкарь Д.Ю., Говоров А.В., Сидоренков А.В., Прилепская Е.А., Ковылина М.В. Ранняя диагностика рака предстательной железы. Методические рекомендации № 19. М.: ООО «Издательский дом «АБВ-пресс», 2015. 52 с
  3. Сидоренков А.В., Говоров А.В., Садченко А.В., Пушкарь Д.Ю. Диагностическая значимость [-2]proPSA и PHI (обзор литературы). Онкоурология. 2014;4:87-95
  4. Пушкарь Д.Ю., Говоров А.В. Маркеры рака предстательной железы. Экспериментальная и клиническая урология. 2011;2:19-21
  5. Bangma C.N., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma. J. Urol. 1997;157:544-547.
  6. Bussemakers M.J., van Bokhoven А., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-5979.
  7. Chun F.K., de la Taille A., van Poppel H., Marberger M., Stenz} A., Mulders P.F., Huland H., Abbou C.C., Stillebroer A.B., van Gils M.P. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur. Urol. 2009;56(4):659-668. doi: 10.1016/j.eururo.2009.03.029.
  8. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., Evans C.L., Gasior C.L., Linton H.J., Carpenter P., Rittenhouse H.G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61:6958-6963.
  9. Maccagnano C., Gallina A., Scattoni V. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol. Int. 2012;89:126-135. doi: 10.1159/000339521.
  10. Epstein J.I., Egevad L., Amin M.B., Delahunt B., Srigley J.R., Humphrey P.A. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244-252.
  11. Epstein J.I., Zelefsky M.J., Sjoberg D.D. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428-435.
  12. Rubin M.A., Girelli G., Demichelis F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol. 2016;69:557-560.
  13. Moch H., Humphrey P.A., Ulbright T.M., Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer; 2016.
  14. Humphrey P.A., Moch H., Cubilla A.L., Ulbright R.M., Reuter V.E. The 2016 WHO classification of tumours of the urinary system and male genital organs - part B: prostate and bladder tumours. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.028

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies